Amro M Stino, Benjamin E Becker
✦ AI-curated · Sources linked
Condensed from the publisher's abstract. An xxcode editorial summary of this publication has not been generated yet.
Paraproteinemic neuropathies present with a myriad of phenotypes and associated underlying plasma cell dyscrasias. This article provides a phenotype-driven approach to the evaluation of paraproteinemic neuropathies, guided by an alignment of clinical, electrodiagnostic, and serologic features.
Published in Continuum (Minneap Minn). The text above is extracted from the publisher's own abstract and has not been edited by xxcode. For clinical decisions, review the original publication.
AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.
This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.
RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…
Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.
Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.
Prefer listening? Personalized audio digests are available with Pro.
Get the 3 most interesting publications in one specialty each week.
Weekly email. Unsubscribe anytime.